EUVIMEDEUVIMED entdecken
Crossref

Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF

Balasubramaniyan Vairappan, Gavin Wright, Sundhar M, T S Ravikumar

European Journal of Pharmacology · 2023

DOI: 10.1016/j.ejphar.2023.176010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Balasubramaniyan Vairappan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Research Lab, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, In…. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Hypertension, Portal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In decompensated cirrhosis, the severity of portal hypertension (PHT) is associated with increased hepatic endothelial nitric oxide synthase (eNOS) trafficking inducer (Nostrin), but the mechanism remains unclear. AIM: To investigate: (1) Whether in cirrhosis-PHT models, ± superimposed inflammation to mimic acute-on-chronic liver failure (ACLF) modulates hepatic nitric oxide synthase trafficking inducer (NOSTRIN) expression, nitric oxide (NO) synthesis, and/or endothelial dysfunction (ED); and (2) Whether the "angiotensin II type 1 receptor blocker" candesartan cilexetil (CC) affects this pathway. CD-1 mice received intraperitoneal carbon tetrachloride injections (CCl4 15% v/v in corn oil, 0.5 mL/kg) twice weekly for 12 wk to induce cirrhosis. After 12 wk, mice were randomized to receive 2-wk oral administration of CC (8 mg/kg) ± LPS. At sacrifice, plasma (biochemical indicators, cytokines, and angiotensin II) and liver tissues (histopathology, Sirius-red stains, and molecular studies) were analysed. Moreover, Nostrin gene knockdown was tested in human umbilical vein endothelial cells (HUVECs). When compared to naïve animals, CCl4-treated animals showed markedly elevated hepatic Nostrin expression (P < 0.0001), while hepatic peNOS expression (measure of eNOS activity) was significantly reduced (P < 0.05). LPS challenge further increased Nostrin and reduced peNOS expression (P < 0.05 for both) in cirrhotic animals. Portal pressure and subsequent hepatic vascular resistance were also increased in all cirrhotic animals following LPS challenge. In CCl4 ± LPS-treated animals, CC treatment significantly reduced Nostrin (P < 0.05) and increased hepatic cGMP (P < 0.01). NOSIP, caveolin-1, NFκB, and iNOS protein expression were significantly increased in CCl4-treated animals (P < 0.05 for all). CC treatment non-significantly lowered NOSIP and caveolin-1 expression while iNOS and NFκB expression was significantly reduced in CCl4 + LPS-treated animals (P < 0.05 for both). Furthermore, Nostrin knockdown significantly improved peNOS expression and associated NO synthesis and reduced inflammation in HUVECs. This study is the first to indicate a potential mechanistic role for the Nostrin-eNOS-NO pathway in cirrhosis and ACLF development. Moreover, this pathway provides a potential therapeutic target given the ameliorative response to Candesartan treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute-On-Chronic Liver FailureHypertension, PortalAnimalsHumansMiceAdaptor Proteins, Signal TransducingCaveolin 1DNA-Binding ProteinsEndothelial CellsInflammationLipopolysaccharidesLiver CirrhosisNF-kappa BNitric Oxide SynthaseNitric Oxide Synthase Type IIIPortal PressureBenzimidazolesBiphenyl CompoundsTetrazolesUbiquitin-Protein Ligases

Stichwörter der Autor:innen

Acute-on-chronic liver failureCandesartan cilexetilCirrhosisCytokinesEndothelial dysfunctionInflammationNOSIPNitric oxideNostrinPortal pressureeNOS

Substanzen

Adaptor Proteins, Signal TransducingCaveolin 1DNA-Binding ProteinsLipopolysaccharidesNF-kappa BNitric Oxide SynthaseNitric Oxide Synthase Type IIIcandesartan cilexetilBenzimidazolesBiphenyl Compounds

Autor:innen und Institutionen

  • Liver Diseases Research Lab, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India. Electronic address: balasubramaniyan.v@jipmer.edu.in.
  • Basildon & Thurrock University Hospitals NHS Foundation Trust, UK; Mid and South Essex NHS Foundation Trust, UK.
  • Liver Diseases Research Lab, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605006, India.
  • Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605006, India.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Vairappan, B., Wright, G., M, S., & Ravikumar, T. S. (2023). Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.176010

Vancouver

Vairappan B, Wright G, M S, Ravikumar TS. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.176010

BibTeX
@article{Vairappan2023,
  author = {Vairappan, Balasubramaniyan and Wright, Gavin and M, Sundhar and Ravikumar, T S},
  title = {Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF},
  journal = {European Journal of Pharmacology},
  year = {2023},
  doi = {10.1016/j.ejphar.2023.176010}
}
Kostenlos starten →